Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:INM

InMed Pharmaceuticals Q1 2027 Earnings Date & Estimates

InMed Pharmaceuticals logo
$1.36 0.00 (0.00%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.00 (+0.37%)
As of 10/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InMed Pharmaceuticals is estimated to report Q1 2027 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q1 2027
Announcement Date
Time
Before Market Opens
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from InMed Pharmaceuticals in Q1 2027

InMed Pharmaceuticals is expected to post earnings of -$94.4436 per share on revenue of $0.30 million. In the same quarter a year earlier InMed Pharmaceuticals reported -$0.44 per share on revenue of $1.12 million.

Consensus Estimates

Consensus EPS
-$94.4436
Expected Revenue
$0.30 million
Prior-Year EPS
-$0.44
Prior-Year Revenue
$1.12 million
Expected Revenue Growth
-73.2%

Recent Track Record

Last Reported
Q4 2026
Last Quarter EPS
-$1.43

Prepare for the Q1 2027 Call

InMed Pharmaceuticals Q1 2027 Earnings FAQ

InMed Pharmaceuticals (NASDAQ:INM) is estimated to report Q1 2027 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

InMed Pharmaceuticals' Q1 2027 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect InMed Pharmaceuticals to post earnings of -$94.4436 per share for Q1 2027.

The consensus revenue estimate for InMed Pharmaceuticals is $0.30 million for Q1 2027.

InMed Pharmaceuticals Earnings Headlines

Comparing ImmuCell (NASDAQ:ICCC) and InMed Pharmaceuticals (NASDAQ:INM)
October 11 at 2:14 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108697
InMed Pharmaceuticals (NASDAQ:INM) Stock: Insider Adar1 Capital Management, Llc Buys 16,431 Shares
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095617
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
 |  Reagan Gold Group (Ad)
InMed Pharmaceuticals (NASDAQ:INM) Stock: Insider Adar1 Capital Management, Llc Purchases 8,307 Shares
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095618
InMed Pharmaceuticals (NASDAQ:INM) Stock: Insider Adar1 Capital Management, Llc Acquires 18,182 Shares
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095483
InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
September 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69621916-inmed-pharmaceuticals-inmed-pharmaceuticals-receives-nasdaq-notification-regarding-minimum-shareholders-equity-compliance-296.htm
See More InMed Pharmaceuticals Headlines

About InMed Pharmaceuticals

InMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder. The company has also advanced INM-088, an eye-drop formulation designed for potential use in glaucoma. The development status of these programs may change as clinical and regulatory work progresses.

In addition to its pharmaceutical programs, InMed expanded into the commercial rare-cannabinoid ingredient market through its acquisition of BayMedica. That business develops and supplies rare cannabinoids, including ingredients for pharmaceutical, nutraceutical, health and wellness, and other commercial applications. InMed is headquartered in Vancouver, British Columbia, and its shares trade on Nasdaq under the symbol INM.

View InMed Pharmaceuticals Profile
Earnings Tools